| Liz Life Guru Llc | |
|
1134 S Lapeer Rd Lowr Level Lapeer MI 48446-3042 | |
| (313) 588-0418 | |
| Not Available |
| Full Name | Liz Life Guru Llc |
|---|---|
| Speciality | Social Worker |
| Location | 1134 S Lapeer Rd Lowr Level, Lapeer, Michigan |
| Authorized Official Name and Position | Elizabeth M Reed (SOLE MEMBER) |
| Authorized Official Contact | 3135880418 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Liz Life Guru Llc 4150 Newark Rd Attica MI 48412-9760 Ph: (313) 588-0418 | Liz Life Guru Llc 1134 S Lapeer Rd Lowr Level Lapeer MI 48446-3042 Ph: (313) 588-0418 |
| NPI Number | 1356850481 |
|---|---|
| Provider Enumeration Date | 09/20/2017 |
| Last Update Date | 09/20/2017 |
| Medicare PECOS PAC ID | 4688949993 |
|---|---|
| Medicare Enrollment ID | O20171011003189 |
News Archive
For her research focusing on the refinement of predictive biomarkers and improving outcomes in the field of metastatic colorectal cancer, Maria Pia Morelli, M.D., Ph.D., has been awarded the 2013 Fight Colorectal Cancer-AACR Fellowship, in memory of Lisa Dubow.
While all Americans will eventually die, CBS's 60 Minutes reports, it may turn some heads to find out how much the government will spend when it happens - in 2008, about $50 billion in the last two months of life. "You might think this would be an obvious thing for Congress and the president to address as they try to reform health care. But what used to be a bipartisan issue has become a politically explosive one - a perfect example of the costs that threaten to bankrupt the country and how hard it's going to be to rein them in."
Omeros Corporation today announced that it has filed an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) to initiate clinical trials evaluating OMS824, the Company's lead compound from its phosphodiesterase 10 (PDE10) program for schizophrenia and other cognitive disorders.
OSI Pharmaceuticals, Inc., Genentech, Inc., and Roche today announced that a Phase III study of Tarceva™ (erlotinib HCl), an investigational HER1/EGFR-inhibitor agent in previously treated patients with non-small cell lung cancer (NSCLC), met its primary endpoint of improving overall survival, with patients receiving Tarceva™ living longer than those in the placebo arm of the study.
The March of Dimes has committed another $2.6 million to support the work of six scientists for the next three years as they study the causes of preterm birth. The 2010 grants bring the six-year total of the March of Dimes Prematurity Research Initiative grant program to more than $15 million.
› Verified 6 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356850481 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | (* (Not Available)) | Primary |
| Provider Name | Elizabeth M Reed |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1356639983 PECOS PAC ID: 1658661756 Enrollment ID: I20160601002642 |
News Archive
For her research focusing on the refinement of predictive biomarkers and improving outcomes in the field of metastatic colorectal cancer, Maria Pia Morelli, M.D., Ph.D., has been awarded the 2013 Fight Colorectal Cancer-AACR Fellowship, in memory of Lisa Dubow.
While all Americans will eventually die, CBS's 60 Minutes reports, it may turn some heads to find out how much the government will spend when it happens - in 2008, about $50 billion in the last two months of life. "You might think this would be an obvious thing for Congress and the president to address as they try to reform health care. But what used to be a bipartisan issue has become a politically explosive one - a perfect example of the costs that threaten to bankrupt the country and how hard it's going to be to rein them in."
Omeros Corporation today announced that it has filed an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) to initiate clinical trials evaluating OMS824, the Company's lead compound from its phosphodiesterase 10 (PDE10) program for schizophrenia and other cognitive disorders.
OSI Pharmaceuticals, Inc., Genentech, Inc., and Roche today announced that a Phase III study of Tarceva™ (erlotinib HCl), an investigational HER1/EGFR-inhibitor agent in previously treated patients with non-small cell lung cancer (NSCLC), met its primary endpoint of improving overall survival, with patients receiving Tarceva™ living longer than those in the placebo arm of the study.
The March of Dimes has committed another $2.6 million to support the work of six scientists for the next three years as they study the causes of preterm birth. The 2010 grants bring the six-year total of the March of Dimes Prematurity Research Initiative grant program to more than $15 million.
› Verified 6 days ago
News Archive
For her research focusing on the refinement of predictive biomarkers and improving outcomes in the field of metastatic colorectal cancer, Maria Pia Morelli, M.D., Ph.D., has been awarded the 2013 Fight Colorectal Cancer-AACR Fellowship, in memory of Lisa Dubow.
While all Americans will eventually die, CBS's 60 Minutes reports, it may turn some heads to find out how much the government will spend when it happens - in 2008, about $50 billion in the last two months of life. "You might think this would be an obvious thing for Congress and the president to address as they try to reform health care. But what used to be a bipartisan issue has become a politically explosive one - a perfect example of the costs that threaten to bankrupt the country and how hard it's going to be to rein them in."
Omeros Corporation today announced that it has filed an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) to initiate clinical trials evaluating OMS824, the Company's lead compound from its phosphodiesterase 10 (PDE10) program for schizophrenia and other cognitive disorders.
OSI Pharmaceuticals, Inc., Genentech, Inc., and Roche today announced that a Phase III study of Tarceva™ (erlotinib HCl), an investigational HER1/EGFR-inhibitor agent in previously treated patients with non-small cell lung cancer (NSCLC), met its primary endpoint of improving overall survival, with patients receiving Tarceva™ living longer than those in the placebo arm of the study.
The March of Dimes has committed another $2.6 million to support the work of six scientists for the next three years as they study the causes of preterm birth. The 2010 grants bring the six-year total of the March of Dimes Prematurity Research Initiative grant program to more than $15 million.
› Verified 6 days ago
Christian Family Services Of Lapeer County Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 441 Clay St, Lapeer, MI 48446 Phone: 810-664-4557 Fax: 810-664-5181 | |
Mclaren Lapeer Region Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1375 N Main St, Lapeer, MI 48446 Phone: 810-667-5701 Fax: 810-667-5949 | |
Tasneem F Hasan Md Pc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 237 Davis Lake Rd Ste A, Lapeer, MI 48446 Phone: 810-660-8477 | |
Catholic Services Of Lapeer Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 700 S Main St, Suite 211, Lapeer, MI 48446 Phone: 810-664-4557 Fax: 810-664-5181 | |
Filter... Info Icon Lapeer County Community Mental Health-sud Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1570 Suncrest Dr, Lapeer, MI 48446 Phone: 810-667-0500 | |
Lapeer County Community Mental Health Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1570 Suncrest Dr, Lapeer, MI 48446 Phone: 810-667-0500 | |
Lapeer Counseling Center Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 700 S Main St Ste 210, Lapeer, MI 48446 Phone: 810-664-4363 Fax: 810-664-4364 |